PharmaCielo Ltd.
PCLOF
$0.07
$0.0250.93%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -20.64% | -49.92% | -14.02% | 64.90% | 212.21% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -20.64% | -49.92% | -14.02% | 64.90% | 212.21% |
| Cost of Revenue | -34.76% | -26.36% | 17.89% | 12.44% | 5.60% |
| Gross Profit | 76.89% | -140.39% | -3,303.28% | 109.13% | 124.96% |
| SG&A Expenses | -21.90% | -23.05% | -14.93% | -38.22% | -26.55% |
| Depreciation & Amortization | -56.48% | -36.06% | -40.05% | -47.48% | -47.82% |
| Other Operating Expenses | 28.18% | -367.49% | -426.22% | -386.99% | -170.65% |
| Total Operating Expenses | -27.11% | -35.69% | -9.34% | -28.82% | -20.25% |
| Operating Income | 31.51% | 25.17% | 7.26% | 49.65% | 47.09% |
| Income Before Tax | 60.48% | 50.53% | 54.68% | 46.27% | 41.64% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 60.48% | 50.53% | 54.68% | 46.27% | 41.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 60.48% | 50.53% | 54.68% | 46.27% | 41.64% |
| EBIT | 31.51% | 25.17% | 7.26% | 49.65% | 47.09% |
| EBITDA | 46.47% | 31.07% | 4.24% | 55.97% | 55.98% |
| EPS Basic | 63.56% | 54.59% | 58.47% | 49.76% | 45.19% |
| Normalized Basic EPS | 30.99% | 19.56% | 10.89% | 38.81% | 34.06% |
| EPS Diluted | 63.56% | 54.59% | 58.47% | 49.76% | 45.19% |
| Normalized Diluted EPS | 30.99% | 19.56% | 10.89% | 38.81% | 34.06% |
| Average Basic Shares Outstanding | 7.83% | 9.40% | 8.98% | 7.51% | 6.84% |
| Average Diluted Shares Outstanding | 7.83% | 9.40% | 8.98% | 7.51% | 6.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |